Premium
Rimonabant (Acomplia): a novel adjunctive treatment for obesity
Author(s) -
Barnett Anthony
Publication year - 2007
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.9
Subject(s) - rimonabant , medicine , action (physics) , adjunctive treatment , obesity , cannabinoid receptor , pharmacology , receptor , antagonist , physics , quantum mechanics
Rimonabant is the first selective cannabinoid‐1 receptor inhibitor for use in the treatment of obesity. In this article Professor Barnett describes its novel mode of action and the results of clinical trials of its efficacy and safety. Copyright © 2007 Wiley Interface Ltd